Back to top
more

Valeant Pharmaceuticals International, Inc. (VRX)

(Real Time Quote from BATS)

$23.40 USD

23.40
6,571,593

-0.83 (-3.43%)

Updated Jul 13, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.

    Kinjel Shah headshot

    Drug Pricing in Focus Again as Trump Tweet Slams Pfizer

    In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".

      Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

      Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

        Company News For Jun 19, 2018

        Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA

          Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue?

          Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa

            Aerie (AERI) reported a narrower-than-expected loss in the first quarter. The launch of the lead drug Rhopressa is underway.

              Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%

              Valeant Pharmaceuticals (VRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                Implied Volatility Surging for Valeant (VRX) Stock Options

                Valeant (VRX) needs investors to pay close attention to the stock based on moves in the options market lately.

                  Why Is Valeant (VRX) Up 4.3% Since Its Last Earnings Report?

                  Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?

                    Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.

                      Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?

                      Investors need to pay close attention to Valeant (VRX) stock based on the movements in the options market lately.

                        Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses

                        Aerie (AERI) incurs a wider-than-expected loss in the fourth quarter due to higher operating expenses.

                          Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?

                          Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.

                            Valeant (VRX) to Settle Allergan Litigation for $290 Million

                            Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.

                              Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio

                              Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.

                                Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

                                Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

                                  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?

                                  Surging implied volatility makes Valeant Pharmaceuticals (VRX) stock lucrative to the option traders.

                                    Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa

                                    Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, ahead of schedule.

                                      Ryan McQueeney headshot

                                      Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?

                                      Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?

                                        Valeant (VRX) in Focus: Stock Moves 11.7% Higher

                                        Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

                                          Implied Volatility Surging for Valeant (VRX) Stock Options

                                          Valeant (VRX) needs investors to pay close attention to the stock based on moves in the options market lately.

                                            Valeant Closes Senior Note Offering, Reprices Term Loan

                                            Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.

                                              Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

                                              Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.

                                                Valeant (VRX) Announces Pricing of Senior Secured Notes

                                                Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.

                                                  Kevin Cook headshot

                                                  Bear of the Day: Herbalife (HLF)

                                                  As Ackman covers his short stock position and limps into puts, Wall Street banks are getting quieter too